Strides Pharma Sciences Ltd - Continued Momentum with Another Strong Quarter
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%. EBITDA stood at Rs. 236 crore, marking a remarkable...
302 Views
US segment drags overall performance
STR reported a lower than expected performance in 2QFY22 due to continued headwinds in the US business. Sales in other regulated markets witnessed...
349 Views
US/Institutional business drives earnings
STR's 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging...
292 Views